Australian Therapeutic Goods Administration certification from the Department of Health and Aging has been received by Ind Swift Laboratories for its Punjab-based facility to manufacture the antibiotic clarithromycin, which is used in the treatment of various respiratory tract infections, according to chief executive V K Mehta.
He added that the company is one of the world's largest manufacturers of clarithromycin, and supplies about one third of total usage. The Australian TGA stated the company complied with requirement of the Australian Code of Good Practice for medicinal products.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze